Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

T cell receptor cross-reactivity expanded by dramatic peptide–MHC adaptability

  • Timothy P. Riley
  • , Lance M. Hellman
  • , Marvin H. Gee
  • , Juan L. Mendoza
  • , Jesus A. Alonso
  • , Kendra C. Foley
  • , Michael I. Nishimura
  • , Craig W. Vander Kooi
  • , K. Christopher Garcia
  • , Brian M. Baker

Producción científica: Articlerevisión exhaustiva

87 Citas (SciVal)

Resumen

T cell receptor cross-reactivity allows a fixed T cell repertoire to respond to a much larger universe of potential antigens. Recent work has emphasized the importance of peptide structural and chemical homology, as opposed to sequence similarity, in T cell receptor cross-reactivity. Surprisingly, though, T cell receptors can also cross-react between ligands with little physiochemical commonalities. Studying the clinically relevant receptor DMF5, we demonstrate that cross-recognition of such divergent antigens can occur through mechanisms that involve heretofore unanticipated rearrangements in the peptide and presenting MHC protein, including binding-induced peptide register shifts and extensions from MHC peptide binding grooves. Moreover, cross-reactivity can proceed even when such dramatic rearrangements do not translate into structural or chemical molecular mimicry. Beyond demonstrating new principles of T cell receptor cross-reactivity, our results have implications for efforts to predict and control T cell specificity and cross-reactivity and highlight challenges associated with predicting T cell reactivities.

Idioma originalEnglish
Páginas (desde-hasta)934-942
Número de páginas9
PublicaciónNature Chemical Biology
Volumen14
N.º10
DOI
EstadoPublished - oct 1 2018

Nota bibliográfica

Publisher Copyright:
© 2018, The Author(s), under exclusive licence to Springer Nature America, Inc.

Financiación

Authors were supported by NIH grants GM118166 and AI29543 (B.M.B.); CA154778 and CA153789 (M.I.N.); and AI103867 (K.C.G.); and American Cancer Society grant IRG-14-195-01 (L.M.H.). T.P.R. and J.A.A. were supported by fellowships from the Indiana CTSI, funded in part by NIH grants TR001107 and TR001108. M.H.G. was supported by a Stanford Graduate Research Fellowship and NIH grant CA216926. J.L.M. was supported by NIH grant CA175127. K.C.G. is supported by the Howard Hughes Medical Institute and the Parker Institute for Cancer Immunotherapy.

FinanciadoresNúmero del financiador
Indiana CTSITR001107, TR001108, CA175127, CA216926
L.M.H.
National Institutes of Health (NIH)AI103867, CA154778, GM118166, CA153789, AI29543
Howard Hughes Medical Institute
American Cancer Society-Michigan Cancer Research FundIRG-14-195-01
National Center for Advancing Translational Sciences (NCATS)TL1TR001107
Parker Institute for Cancer Immunotherapy

    ASJC Scopus subject areas

    • Molecular Biology
    • Cell Biology

    Huella

    Profundice en los temas de investigación de 'T cell receptor cross-reactivity expanded by dramatic peptide–MHC adaptability'. En conjunto forman una huella única.

    Citar esto